ReviewClinical interventions in aging2010
Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.
Review in Clinical interventions in aging, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Efficacy of acetylcholinesterase inhibitors on reducing hippocampal atrophy rate: a systematic review and meta-analysis.BMC neurology · 2025Pooled it
- Efficacy and safety of galantamine treatment for patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.Journal of neural transmission (Vienna, Austria : 1996) · 2015Pooled it
- Current and emerging drug treatment options for Alzheimer's disease: a systematic review.Drugs · 2011Pooled it
- Analysis of the Efficacy of Acetylcholinesterase Inhibitors in the Treatment of Alzheimer's Disease, Literature Review.International journal of molecular sciences · 2026Review
- Preformulation Study of Controlled-Release Galantamine Matrix Tablets Containing Polyethylene Oxide, Hydroxypropyl Methylcellulose, and Ethylcellulose.Pharmaceutics · 2025Article
- Nanomedicine: A New Frontier in Alzheimer's Disease Drug Targeting.Central nervous system agents in medicinal chemistry · 2025Review
- Transdermal Therapeutic Systems for the Treatment of Alzheimer's Disease: A Patent Review.CNS & neurological disorders drug targets · 2024Review
- Current and Future Nano-Carrier-Based Approaches in the Treatment of Alzheimer's Disease.Brain sciences · 2023Review
- Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives.Pharmaceutics · 2022Review
- Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer's Disease and Future Perspectives.Journal of Alzheimer's disease reports · 2022Review
- Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis.International journal of molecular sciences · 2021Review
- Neuroprotective Effect ofInternational journal of molecular sciences · 2020Article
- Galantamine inhibits β-amyloid-induced cytostatic autophagy in PC12 cells through decreasing ROS production.Cell proliferation · 2018Article
- Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease.PloS one · 2014Article
- Article
- The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.CNS drugs · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An extended release form of the cholinesterase inhibitor (ChEI) drug galantamine (galantamine-ER) was developed, chiefly to increase adherence to medication regimes in patients with mild-to-moderate Alzheimer's disease (AD). Except for predicted differences in (C(max)) and t(max), comparable doses of once daily galantamine-ER and regular, immediate release galantamine, (galantamine-IR), are pharmacologically equivalent. A 24-week randomized, double-blind, placebo-and active-controlled, multicenter phase III trial, which compared galantamine-IR, galantamine-ER and placebo in subjects with mild to moderate AD (mini-mental state examination [MMSE] score range, 10 to 24) showed that both formulations of galantamine were significantly better than placebo in terms of cognition, although not with regard to global change. There was no difference in drug-related adverse events between galantamine-ER and galantamine-IR. Since its release onto the market galantamine-ER has enjoyed wide popularity and a recent surveillance study suggests that it has the highest 1-year persistence rate of all the ChEIs.
Indexed as
Identifiers
20169037PMC2817936W1987028660What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.